Opendata, web and dolomites

TWO-BIRDS SIGNED

A feasibility study for SYT-510, a first-in-class drug to treat neuropsychiatric disorders through restoring overall balance in brain chemistry

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TWO-BIRDS project word cloud

Explore the words cloud of the TWO-BIRDS project. It provides you a very rough idea of what is the project "TWO-BIRDS" about.

neural    dysregulated    stress    post    endocx    termed    deals    sustainable    family    establishing    balance    patients    flashbacks    thereby    eventual    first    final    mechanism    patient    severe    attractive    coerced    regulatory    stage    neuroregulator    ineffective    plan    safe    downstream    experiences    preclinical    risk    70    anxiety    commercialize    dependency    circuits    market    drug    synendos    small    symptoms    consolidate    15    ptsd    understand    pharmaceutical    population    self    partnering    disorder    selective    action    investor    chemistry    clinician    manner    victims    pharma    circuit    start    triggers    paradigm    compound    syt    thoughts    endocannabinoid    unforgiving    510    chemistries    disorders    trauma    treatment    restoring    birds    co    molecule    inhibitors    million    intrusive    safety    feasibility    sales    limiting    brain    hold    ready    seris    people    relive    pharmacokinetic    traumatic    unfortunately    provoke    nightmares    psychological    combined    disrepair    cognitive    modulate    restore    clinical    never    drugs    reuptake    function    master    demonstrated    anti    profile    companies    relief    business    regulate   

Project "TWO-BIRDS" data sheet

The following table provides information about the project.

Coordinator
SYNENDOS THERAPEUTICS AG 

Organization address
address: SWISS INNOVATION PARK, GEWERBESTRASSE 24
city: ALLSCHWIL
postcode: 4123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SYNENDOS THERAPEUTICS AG CH (ALLSCHWIL) coordinator 50˙000.00

Map

 Project objective

PTSD affects over 15 million people in Europe. So far, 70% never find relief. New drugs that restore the endocannabinoid (endoCx) neural circuit hold potential to change this paradigm.

Post-traumatic stress disorder, known as PTSD, is one of the most unforgiving psychological disorders. As victims of trauma, PTSD patients are coerced by their dysregulated brain chemistries to relive their traumatic experiences, where specific triggers provoke symptoms such as flashbacks, intrusive thoughts, nightmares and severe anxiety. Unfortunately, current drugs address only specific downstream neural circuits and are highly ineffective. The endoCx is highly dysregulated in PTSD, and as a 'master neuroregulator', drugs that restore its function in a safe and sustainable manner have strong potential to be the first effective treatment for PTSD.

Synendos is a pharmaceutical start-up who have identified a new family of drugs that modulate the endoCx via a new mechanism-of-action. Termed SERIs, or, ‘selective endocannabinoid reuptake inhibitors’, these small molecule drugs regulate the endoCx system in a self-limiting manner, thereby restoring balance to brain chemistry without risk of drug dependency or cognitive disrepair. Our lead compound SYT-510 is at the stage of preclinical development, where it has demonstrated effective anti-anxiety activity, favourable pharmacokinetic characteristics and a strong safety profile.

We aim to commercialize SYT-510 through establishing partnering deals with pharma companies for its co-development and eventual sales. With a patient population of over 30 million (in EU/US combined), PTSD is an attractive market for drug development.

TWO-BIRDS project: The main aims of this feasibility study are to 1) work to further understand clinician and patient needs, 2) define a detailed plan for final preclinical, clinical and regulatory activities and 3) consolidate new information into an investor-ready business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TWO-BIRDS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TWO-BIRDS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CAARESYS (2019)

CAARESYS: vehicle passenger monitoring system based on contactless low emission radio frequency radar.

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More